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hIntroduction:Misfolded aggregated proteins and neuroinflammation significantly contribute to amyotrophic lateral sclerosis (ALS)
pathogenesis, hence representing therapeutic targets to modify disease expression. Rapamycin inhibits mechanistic target of
Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and
animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in
which it reduced neuronal loss and TDP43 inclusions. Rapamycin also expands regulatory T lymphocytes (Treg) and increased Treg
levels are associated with slow progression in ALS patients.
Therefore, we planned a randomized clinical trial testing Rapamycin treatment in ALS patients.
Methods:RAP-ALS is a phase II randomized, double-blind, placebo-controlled, multicenter (8 ALS centers in Italy), clinical trial. The
primary aim is to assess whether Rapamycin administration increases Tregs number in treated patients compared with control arm.
Secondary aims include the assessment of safety and tolerability of Rapamycin in patients with ALS; the minimum dosage to have
Rapamycin in cerebrospinal fluid; changes in immunological (activation and homing of T, B, NK cell subpopulations) and inflammatory
markers, and on mTOR downstream pathway (S6RP phosphorylation); clinical activity (ALS Functional Rating Scale-Revised,
survival, forced vital capacity); and quality of life (ALSAQ40 scale).
Discussion: Rapamycin potentially targets mechanisms at play in ALS (i.e., autophagy and neuroinflammation), with promising
preclinical studies. It is an already approved drug, with known pharmacokinetics, already available and therefore with significant
possibility of rapid translation to daily clinics. Findings will provide reliable data for further potential trials.
Ethics and dissemination: The study protocol was approved by the Ethics Committee of Azienda Ospedaliero Universitaria of
Modena and by the Ethics Committees of participating centers (Eudract n. 2016-002399-28) based on the Helsinki declaration.
Abbreviations: DFS= progression rate, ADR= adverse drug reaction, AE= adverse events, ALS= amyotrophic lateral sclerosis,
ALSAQ-40 = Amyotrophic Lateral Sclerosis Specific Assessment Questionnaire, ALSFRS = Amyotrophic Lateral Sclerosis
Functional Rating Scale, ALT (SGPT) = alanine aminotransferase, ANOVA = analysis of variance, AST (SGOT) = aspartate
aminotransferase, BBB = blood–brain barrier, C9orf72 = chromosome 9 open reading frame 72, CNS = central nervous system,
CRO = contract research organization, CSF = cerebrospinal fluid, CYP3A4 = cytochrome P-450 3A4, DSMB = Data Safety and
Monitoring Board, eCRF= electronic case report form, FoxP3= forkhead box P3, FTLD= frontotemporal lobar degeneration, FUS=
fused in sarcoma, FVC = forced vital capacity, gamma GT = gamma-glutamyltransferase, HIV = human immunodeficiency virus,his work was supported by the Italian Agency for the Research on Amytrophic Lateral Sclerosis (AriSLA).
he authors have no conflicts of interest to disclose.
Department of Neuroscience, St. Agostino-Estense Hospital, Azienda Ospedaliero Universitaria di Modena, University of Modena and Reggio Emilia, Modena, b Unit of
tatistics, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria di Modena,
odena, c Department of Neurosciences, Rehabilitation Ophthalmology, Genetics, Mother and Child Disease, Ospedale Policlinico San Martino, Genova, d “Rita Levi
ontalcini”—Department of Neurosciences, ALS Centre, University of Turin and Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, e 3rd
eurology Unit and ALS Centre, IRCCS “Carlo Besta” Neurological Institute, Milan, f NEuroMuscular Omnicenter, Serena Onlus Foundation, Milan, g ALS Centre,
eurologic Clinic, Maggiore della Carità University Hospital, Novara, h ALS Center, “Salvatore Maugeri” Clinical-Scientific Institutes, Milan, i Department of
eurosciences, University of Padua, Padua,, j Department of Life Sciences, University of Modena and Reggio Emilia, Modena, k Department of Medical and Surgical
ciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.
Correspondence: Jessica Mandrioli, Department of Neuroscience, St. Agostino-Estense Hospital, Azienda Ospedaliero Universitaria di Modena, Via Pietro Giardini n.
355, 41100 Modena, Italy (e-mail: j.mandrioli@ausl.mo.it).
opyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.
his is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in
ny medium, provided the original work is properly cited.
edicine (2018) 97:24(e11119)
eceived: 21 May 2018 / Accepted: 23 May 2018
ttp://dx.doi.org/10.1097/MD.0000000000011119
1
HPLC= high-performance liquid chromatography, LC–MS/MS= high-performance liquid chromatography with mass spectrometry,
Mandrioli et al. Medicine (2018) 97:24 MedicineLDH = lactate dehydrogenase, MedDRA = Medical Dictionary for Regulatory Activities, MN = motor neuron, MRC = Medical
Research Council, MS=mass spectrometry, mSOD1=mutant SOD1, mTOR=mechanistic target of rapamycin, mTORC1= target
of rapamycin (mTOR) Complex 1, OPTN = optineurin, p62 = nucleoporin p62, P-gp = p-glycoprotein., RCT = randomized clinical
trial, ROS = reactive oxygen species, S6RP = S6 ribosomal protein, SAE = serious adverse event, SMCR8 = Smith–Magenis
syndrome chromosome region, candidate gene 8, SOD1 = superoxide dismutase 1, SPIRIT = Standard Protocol Items for
Randomized Trials, SQSTM1 = sequestosome 1, TBK1 = Tank-Binding Kinase 1, TDP43 = Tar DNA binding protein-43, TH = T-
helper cell, Treg = regulatory T-lymphocytes, UBIs = ubiquinate inclusions, UBQLN2 = ubiquilin 2, VAPB = vesicle-associated
membrane protein-associated protein b, VCP = Valosin Containing Protein, WMA = world medical association.
Keywords: amyotrophic lateral sclerosis, autophagy, randomized clinical trial, Rapamycin, Treg lymphocytes
1. Introduction 2. MethodsProtein aggregates into neurons and glial cells are common
features of amyotrophic lateral sclerosis (ALS) pathology, and
have a key role in ALS initiation and progression: TDP43
proteinopathy is a hallmark of >95% of sporadic/nonmutated
ALS.[1,2] Protein degradation machinery and autophagy have a
crucial role in dealing with misfolded aggregated proteins.[3] In
ALS several genes (UBQLN2, SQSTM1, OPTN, VCP, TBK1)
have strong links with protein degradation pathways as their
products contribute to recruitment of ubiquitinated proteins to
the autophagosome. Autophagy is also required for the removal
of aberrant stress granules involved in ALS pathology [4] and for
downregulation of inflammasome activity, which is activated in
response to cellular inclusions formation.[5] TBK1, OPTN, and
SQSTM1 converge on autophagy and neuroinflammation,
suggesting that compounds which affect both pathways may
be promising.[1] A recent paper showed a function for C9orf72 at
lysosomes, with impaired responses of mechanistic Target of
Rapamycin (mTOR) Complex 1 (mTORC1) signaling to changes
in aminoacid availability after depletion of either C9orf72 or
SMCR8.[6]
mTOR integrates signals to elicit critical outputs, including
growth control, protein synthesis, gene expression, andmetabolic
balance. [7] The action of Rapamycin is based on mTORC1
inhibition. mTORC1 targets regulatory proteins in cell signaling
and regulates autophagy by inhibiting the unc-51-like kinase 1
complex. Inhibition of mTORC1 by Rapamycin stimulates
autophagy, through the formation of autophagosome from the
phagophore.
mTOR acts on homeostasis of T cells. Indeed, naive CD4+ T
cells can develop into TH1, TH2, or TH17 effectors using
pathways promoted by mTOR. Conversely, mTOR inhibits the
induction of regulatory T lymphocytes (Treg), cells that down-
regulate immune activation. Inhibition of mTORC1 by Rapa-
mycin expands Tregs and, in mSOD1 mice, increased Tregs and
induction of M2 microglia (with anti-inflammatory properties)
were associated with stable phase of disease. In ALS patients,
blood percentage of Tregs inversely correlated with progression
rate, and FoxP3 levels were early predictors of ALS progression
and survival.[8] Thus, Tregs may be considered important
therapeutic targets in ALS addressed by Rapamycin.
Rapamycin has been tested in several neurodegeneration
models because it is an mTOR-dependent autophagy activator,
and accelerates the removal of abnormal accumulation of
aggregated proteins [9,10] with beneficial effects.[7] Rapamycin
administration exerted a beneficial effect in several cell lines,[9,11–
13] and in several ALS animal models, improving motor and
cognitive phenotype.[14–18]
Based on these premises, we are going to perform a clinical trial
in ALS patients with Rapamycin, a drug that enhances autophagy,
facilitates TDP43 clearance, and regulates immune responses.22.1. Objectives
The primary objective is to assess whether different Rapamycin
doses increase Treg number in ALS patients compared with the
control arm.
Secondary objectives include the following:1. Assessment of Rapamycin safety and tolerability in a cohort of
ALS patients: occurrence of adverse events (AEs), changes on
clinical examination including vital signs and weight, and
laboratory examinations (biochemistry, hematology and
urinalysis) will be registered throughout the entire study
duration.
Biological assessment: To analyze Rapamycin efficacy in2.
inhibiting MTOR pathway, by quantifying the phosphoryla-
tion of the S6 ribosomal protein (S6RP) comparing baseline
and weeks 8, 18 (treatment end), 30, and 54 between
Rapamycin arms and placebo arm. To identify changes in
activation and homing capabilities of different T, B, NK cell
subpopulations comparing baseline and weeks 8, 18 (treat-
ment end), 30, and 54 between Rapamycin arms and placebo
arm. To study Rapamycin effects on different biomarkers
(including peripheral and CSF biomarkers, that is, creatinine
and albumin, CK, vitamin D, plasma/CSF neurofilament
heavy/light chain protein) comparing baseline and week 8, 18
(treatment end), 30, and 54 between Rapamycin arms and
placebo arm. To identify Rapamycin-induced changes in
inflammatory status, by the molecular analysis of the
inflammasome system baseline and week 8, 18 (treatment
end), 30, and 54 between Rapamycin arms and placebo arm.
To assess Rapamycin capacity to pass through blood–brain
barrier (BBB).
Clinical assessment: to assess changes in Amyotrophic Lateral3.
Sclerosis Functional Rating Scale (ALSFRS)-Revised from
baseline to weeks 4, 8, 12, 18, 30, 42, and 54 in placebo and
treatment arms; overall survival from randomization to date of
documented death or tracheostomy; survival rate at weeks 18,
30, 42, and 54; forced vital capacity (FVC) score from baseline
to weeks 4, 8, 12, 18, 30, 42, and 54.
Quality of life assessment: ALSAQ-40 from baseline to weeks4.
8, 18, 30, and 54 in treatment and placebo arms.2.2. Design of the study
This is a multicenter, randomized, double-blind, placebo-
controlled, phase II clinical trial. It has been designed following
the guidelines on clinical investigation of medicinal products for
the treatment of ALS provided by the European Medicines
Agency and adopted by the Agenzia Italiana del Farmaco. The
Figure 1. design of the study RAP-ALS.
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suggestions of the Data Safety and Monitoring Board (DSMB).
The DSMB includes:
T
In
In
Pa
Fa
Ag
Di
Pa
Pa
Pa
Pa
Pa
Us
AL
disProf. Lawrence Korngut, University of Toronto.
Prof. Paola Minghetti, University of Milan. Dr Graziella Filippini, IRCCS Foundation “Carlo Besta”
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Dr Ettore Beghi, IRCCS “Mario Negri” Institute, Milan.
The protocol (version 2, April 21, 2017) has been designed
adhering to the Standard Protocol Items for Randomized Trials
(SPIRIT). The trial has been registered on EU Clinical Trialsable 1
clusion and exclusion criteria for RAP-ALS trial.
clusion criteria
tient diagnosed with a laboratory supported, clinically “probable” or “definite”
ALS according to Revised EEC
Prior us
milial or sporadic ALS Prior all
e between 18 and 75 y old Any me
limite
tuber
sease duration from symptoms onset 18 mo at the screening visit Severe
inters
tient treated with a stable dose of Riluzole (100 mg/d) for ≥30 d before
screening
White b
tients with a weight >50kg and a BMI ≥18 Patient
tient with a FVC ≥70% predicted normal value for gender, height, and age
at the screening visit
Women
tient able and willing to comply with study procedures as per protocol Participa
tient able to understand, and capable of providing informed consent at
screening visit before any protocol-specific procedures
Patients
muta
e of effective contraception both for males and females
S= amyotrophic lateral sclerosis, BMI=body mass index, EEC=El Escorial Criteria, FVC= forced vital ca
mutase.
3Register (https://www.clinicaltrialsregister.eu/ctr-search/trial/
2016-002399-28/IT) and on Clinicaltrials.gov (https://clinical
trials.gov/ct2/show/NCT03359538?term=rapamycin&cond=
Amyotrophic+Lateral+Sclerosis&rank=1)
Figure 1 shows the design of the study.
2.3. Eligibility criteria
Patients affected by probable (clinically or laboratory supported)
or definite ALS [19] will undergo screening procedures that must
be completed during the 14-day screening period. All patients
must adhere to inclusion and exclusion criteria (Table 1) throughExclusion criteria
e of Sirolimus
ergy/sensitivity to Sirolimus or macrolides
dical disorder that would make immunosuppression contraindicated, including but not
d to, acute infections requiring antibiotics, patients with known diagnosis of HIV,
culosis, hepatitis B or C infection or history of malignancy
comorbidities (heart, renal, liver failure), autoimmune diseases or any type of
titial lung disease
lood cells <4000/mm3, platelets count <100,000/mm3, hematocrit <30%
who underwent non invasive ventilation, tracheotomy and/or gastrostomy
who are pregnant or breastfeeding
tion in pharmacological studies within the last 30 d before screening
with known SOD1 mutation or with FALS and family members carrying SOD1
tion
pacity, NIV=noninvasive ventilation, PEG=percutaneous endoscopic gastrostomy, SOD1= superxyde
Mandrioli et al. Medicine (2018) 97:24 Medicineclinical evaluation and laboratory and instrumental assessment.
Screening assessments include blood sampling, biochemical and
pregnancy evaluations (for fertile females) which will be
performed in the site’s local laboratory, general and neurological
examinations, MRC, ALSFRS-R, chest radiography and ECG,
and spirometry.2.4. Randomization
Eligible patients will be randomized strictly sequentially,
according to a randomization list prepared by the Biostatistician
of the University of Modena.
All patients will receive a unique patient identification number
at screening visit when signing the informed consent and before
any study procedures are performed. Sixty-three patients will be
randomized in the following 3 groups:
21.
2.21 patients will receive Rapamycin 2mg/m /d + riluzole.
21 patients will receive Rapamycin 1mg/m2/d + riluzole3. 21 patients will receive placebo + riluzole2.5. Stratification
Randomization will be performed online. Patients will be
stratified according to DFS (</≥0.7),[20] with 1:1:1 allocation
in 3 treatment arms (Rapamycin 1mg/m2/d; Rapamycin 2mg/m2/
d, placebo). The investigators will randomize patients directly
online. Treatment will begin within 14 days from randomization.
In case of discontinuation from the study, the randomization
number will not be reused.2.6. Experimental drug preparation
Pfizer S.r.L. gave the active treatment (Rapamycin) free of charge.
Euromed Clinical Supply Services (ECLISSE) (Cantù (Como),
Italy; http://www.css.euromed.it/en/) prepared the active formu-
lation and the placebo. The active powder and the investigational
drug have been produced complying the Good Manufacturing
Practices of the European Union for active pharmaceutical
ingredients and ICH Q7A guidelines. Verum and placebo are
identical and unrecognizable tablets by form size, weight, and
color, and will be indistinguishable to patients and neurologists.2.7. Treatment and blindness
This study is a phase II randomized, double-blind, placebo-
controlled, multicenter, clinical trial (RCT) to test Rapamycin in
ALS patients. The study will include 63 ALS patients (EL Escorial
Revised Criteria, sporadic and familial) with 1:1:1 allocation in 3
groups of 21 subjects each; treatment will be double blinded, and
will last 18 weeks. Active treatment will include oral Rapamycin
at 1mg/m2/d or 2mg/m2/d.
Rapamycin levels will be regularly measured and revealed only
to an independent monitor, who will input Rapamycin levels on a
separate eCRF, and on the basis of that value dosing changes may
be performed at each treatment dispensation directly through
eCRF (and blinded to caring neurologists who will supply bottles
identified by a number and corresponding to different blinded
doses) to keep Rapamycin levels from 4 to 12ng/mL.
Computerized randomization will be stratified by DFS (</≥0.7).
After treatment end (week 18) patients will be followed up for
further 36 weeks. This large period of follow-up has the aim to
assess potential late side effects of the treatment and to assess4whether eventual biological or clinical effects of the treatment
with respect to placebo, may last after drug discontinuation.
For the first 10 patients enrolled, clinical and biological safety
assessments will be performed every week for the first month, and
then every 2 weeks until the end of treatment. For the remaining
53 patients clinical assessments will be performed every 2 weeks
for the first month, and then every 4 weeks during treatment
duration.
If at either the interim or the final analyses safety concerns will
arise, the trial will be stopped and all available data will be
reviewed by the Study Steering Committee.
Table 2 shows study procedures to be undertaken.2.8. Concomitant treatments
Patients must have been treated for a minimum of 1 month
with a stable dose of riluzole (100mg/d) at baseline. Safety
issues related to riluzole will be managed according to usual
practice.
Treatment of ALS impairments (nutrition, respiration, motric-
ity, communication) will be done with a multidisciplinary
approach and accordingly to EFNS Guidelines for ALS patients’
management.[21]
As for prohibited treatments Rapamycin is known to be a
substrate for both cytochrome P-450 3A4 (CYP3A4) and p-
glycoprotein (P-gp). Inducers of CYP3A4 and P-gp may decrease
Rapamycin concentrations, whereas inhibitors of CYP3A4 and
P-gp may increase Rapamycin concentrations. Concomitant use
of strong inducers is not recommended, whereas it is forbidden
concomitant use of strong inhibitors of CYP3A4 and P-gp.
Alternative agents with lesser interaction potential with
Rapamycin should be considered.
Immunosuppressants may affect response to vaccination.
Therefore, during treatment with Rapamycin, vaccination may
be less effective. Because grapefruit juice inhibits the CYP3A4-
mediatedmetabolism of Rapamycin, it will be not allowed to take
with or be used for dilution of Rapamycin.2.9. Outcomes
The primary outcome is represented by the change from baseline
to week 18 in Treg number in ALS patients treated with
Rapamycin compared with the control arm.
Secondary outcomes are as follows:1. Safety: Occurrence of AEs and per-treatment arising changes
in physical examination, vital signs (blood pressure, pulse
rate, and body temperature), body weight, and clinical
laboratory tests (biochemistry, hematology). MedDRA
dictionary is going to be used for reporting.
Rapamycin levels in CSF at week 18 (high-performance2.
liquid chromatography (HPLC) with mass spectrometry
(MS) (LC–MS/MS).
Change from baseline to each time point (weeks 8, 18, 30,3.
and 54) of the phosphorylation of the S6 ribosomal protein
(S6RP) comparing Rapamycin arms and placebo arm.
Change from baseline to each time point (week 8, 18, 30, and4.
54) of the activation and homing capabilities of different T,
B, NK cell subpopulations comparing Rapamycin arms and
placebo arm.
Changes from baseline to each time point (weeks 8, 18, 30,5.
and 54) in different biomarkers (including peripheral and
CSF biomarkers that is, creatinine and albumin, CK, vitamin
Mandrioli et al. Medicine (2018) 97:24 www.md-journal.comD, plasma/CSF neurofilament heavy/light chain protein)
comparing Rapamycin arms and placebo arm.
Changes from baseline to each time point (weeks 8, 18, 30,6.
and 54) in inflammatory status (molecular analysis of the
inflammasome system) comparing Rapamycin arms and
placebo arm.
Change from baseline to each time point (weeks 4, 8, 12, 18,7.
30, 42, and 54) of ALSFRS-R.
Survival defined as the time from randomization to the date8.
of documented death or tracheotomy.
Survival rate at weeks 18, 36, and 54.9.
10. Change of FVC from baseline to each time point (weeks 4, 8,
12, 18, 30, 42, and 54).
Absolute and relative change from baseline in ALSAQ-4011.
(Amyotrophic Lateral Sclerosis Specific Assessment Ques-
tionnaire at weeks 4, 8, 12, 18, 30, 42, and 54).2.10. Adverse events
AEs (serious and nonserious AEs), adverse drug reaction (ADR),
and unexpected ADR will be defined accordingly to “ICH
Guidance for Clinical Safety Data Management: Definitions and
Standards for Expedited Reporting.”
All AE occurring between the first study-related procedure and
the last study-relatedprocedurewill be reported.Thosemeeting the
definition of serious AE (SAE) will be reported in an ad hoc SAE
Form; theywill be reported to coordinating centerwithin 24hours.
The following AEs have been reported during the use of
Rapamycin, mainly in transplanted patients and in association
with other drugs (Table 3).
Investigators must adhere to specific safety rules established
for the following toxicities, regardless of the causal relationship
to study treatment: respiratory toxicity; metabolic toxicity;
cardiovascular toxicity; gastrointestinal toxicity; hematological
toxicity; genitourinary toxicity; renal toxicity; reproductive
system and pregnancy; hypersensitivity Reactions; skin toxicity;
carcinogenicity; and increased susceptibility to infection.
The risk management plan for AEs not described above and
suspected to be related to study treatment is as follows: At the first occurrence of moderate AE (grade 2): study
treatment will be interrupted until AEs has returned to baseline
value or mild intensity, then resumed at the same dose level
according to local investigator judgment.
If the same moderate AE reoccurs, study treatment will be
interrupted.
In case of severe AE (grade 3), study treatment will be
interrupted until AE has returned to baseline level or mild
intensity, then resumed with a dose reduction (1 step).
In case of life-threatening or disabling AE (grade 4), study
treatment must be definitely discontinued.
2.11. Safety assessment
Safety will be assessed on the following variables: occurrence of
AEs and per-treatment arising changes in physical examination,
vital signs (blood pressure, pulse rate, and body temperature),
body weight, and clinical laboratory tests (biochemistry,
hematology). MedDRA dictionary is going to be used for
reporting.
All AEs will be actively collected at each visit, from
spontaneous declarations of the patient as well as from oral5inquiry and clinical examination. All concomitant medications
and/or therapies should be documented in the patient file and
reported in the electronic Case Report Form (eCRF).
The following biological parameters will be assessed according
to study flow chart (Table 2)—hematology: count of red blood
cells, hemoglobin, hematocrit, total white blood cells count,
platelet count, and a differential count including neutrophils,
lymphocytes, monocytes, eosinophils, and basophils; biochemis-
try includes urea, creatinine, albumin, protein electrophoresis,
AST (SGOT), ALT (SGPT), gamma GT, LDH, cholesterol,
triglycerides, sodium, potassium, glucose; screening for infectious
diseases including HIV, hepatitis B, hepatitis C, and tuberculosis.
An electrocardiogram and chest X-ray (only posterior–anterior
view) will be performed at screening. At treatment end (week 18)
these exams can be repeated based on clinical opinion of the
caring neurologist.
A physical examination including vital signs (systolic and
diastolic arterial pressure, heart rate) and body weight will be
performed according to the Visit Schedule (Table 2). Check for
adequate contraception will be performed at every visit.
Respiratory function will be monitored with FVC.
Stopping rules for single patient have been established for each
AE.
Stopping rule for the RCT has been established too. We will
consider the following list of toxicities as acceptable: peripheral
edema, hypertriglyceridemia, hypercholesterolemia, constipa-
tion, arthralgia, thrombocytopenia (not severe), anemia (not
severe), leukopenia (not severe), rash, hypertension, increased
creatinine, abdominal pain, diarrhoea, headache, fever, urinary
tract infection, nausea, lymphocele, tachycardia, stomatitis,
abnormal healing, increased lactic dehydrogenase, hypokalemia
(not severe), diabetes mellitus, epistaxis, ovarian cysts, and
menstrual disorders (amenorrhea and menorrhagia).
The study will be stopped by the DSMB in case of >30% of
patients experience one of the following side effects: pneumonia,
sepsis, venous thromboembolism, thrombotic thrombocytopenic
purpura/hemolytic uremic syndrome, severe leukopenia or
anemia or thrombocytopenia, bone necrosis, melanoma, and
skin cancer. In other words, the trial will be stopped if any of the
abovementioned SAEs occurs in ≥6 patients.
As for mild and moderate AEs, the DSMB will be notified if
50% of all subjects report a given mild or moderate severity
adverse effect.2.12. Data recording and data monitoring
The investigators will collect data by entering them directly into
the trial database, through electronic case report forms ad hoc
developed. At the end of the RCT, database will be locked and an
expert Statistician will check the database and extract all data for
statistical analyses.
The study will be monitored by a certified contract research
organization (CRO). A monitor will be in charge of safety data
downloads and review on monthly basis (AEs), laboratory data
downloads, including Rapamycin levels on fortnightly basis. Data
safety and monitoring board (DSMB) meetings will be scheduled
(starting when the first 10 patients enrolled would have been
treated for 3 months and then when 50% of patients would have
completed at leastweek8of treatment andsubsequentlyafter every
3months).All SAEswill be reviewedby theDSMB.As formild and
moderate AEs, the DSMB will be notified if 50% of all subjects
report a given mild or moderate severity adverse effect.
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The sample size has been estimated considering as the primary
outcome measure the proportion of positive response (Tregs
number increase) at treatment end (18 weeks) in patients treated
with Rapamycin versus placebo.
ALS patients have a slight reduction of Treg% (mean±SD: 2.1
±0.7) with respect to healthy controls (2.6±0.6) (Treg%
calculated on total lymphocytes; normal values of total
lymphocytes: 1000–4500/mL; normal values of total Treg:
71.5±17/mL).[22]
Slowly progressive ALS patients have a number of Tregs that is
equal to healthy controls, whereas fast progressors have 31%
fewer Tregs than slowly progressing patients, and Treg % is
inversely correlated with the rate of disease progression.[8] These
data indicate that ALS patients have 60±17Treg/mL (fast
progressors: 49.3Treg/mL; slow progressors: 71.5Treg/mL). As a
result, a “positive response” can be considered an increase of the
proportion of Tregs by ≥30%. The null hypothesis is that
Rapamycin does not increase significantly the proportion of
positive responses in treated patients at 18 weeks compared with
their baseline stage and to placebo group. The alternative
hypothesis is that Rapamycin determines a proportion of positive
responses in ≥50% of treated patients compared with a
maximum 5% of patients in the placebo group. The study has
been designed to reject the null hypothesis with an alpha error of
0.025 (to take into account a multiple comparison with a control
arm) and a power of 0.80. For this purpose, a sample of 54
patients randomized in 3 treatment arms would be needed.
Considering an average drop out of 15% then a recruitment of 63
patients will be necessary.
2.14. Statistical analyses
Separate analyses will be performed in1. all randomized subjects receiving ≥1 dose of study medication
(intention-to-treat population);
all randomized subjects excluding protocol deviations (per2.
protocol, PP population).
Descriptive statistics will be performed comparing the 2 groups
of Rapamycin treatment and placebo. Continuous variables will
be described using mean and standard deviation or median and
interquartile range; categorical variables will be described as
counts and percentages.
Safety analysis will be performed in all subjects receiving ≥1
dose of the experimental drug. All AEs, SAEs, and AEs leading to
treatment discontinuation will be recorded according to ICH
Guidelines, listed, and compared in the treatment arms at any
follow-up visit and at the end of the study.
Differences in tracheostomy-free survival (Kaplan–Meier
method) between the treated groups and placebo group will be
compared using the log-rank test. Cox’s proportional hazard
model would be used to adjust for any possible unbalanced
prognostic factors. Statistical significance will be set at .05 level
for a 2-tailed test. Missing data will be handled using the last
observation carried forward.
Immune response to Rapamycin will be analyzed as the
difference in positive response to Rapamycin (mean Tregs
increase >30%) between the placebo group and the Rapamycin
groups. This will be calculated with the use of Treg data obtained
at baseline and at week 18.
We will compare the mean values of S6RP phosphorylation, of
different T, B, NK cell subpopulations, of biomarkers,8inflammasome, cytokines, comparing baseline and treatment
end (18 weeks) between Rapamycin and placebo arm. Mean
differences in plasma concentrations from baseline to week 18 in
the 2 treatment arms will be calculated and compared using t test
or Wilcoxon–Mann–Whitney test.
Themean change over time for the same variables as above will
be assessed using repeated measures ANOVA, with treatment as
between-subjects factor and time as within-subjects factor.
Different models will be used, each with a different biomarker
of activity as the dependent variable. Models will be adjusted for
any unbalanced distribution of the main prognostic factors (e.g.,
age) between the 2 treatment arms.2.15. Role of participating centers
Our study group includes 8 centers (Turin, Modena, Genoa,
Padua, Novara, and 3 centers in Milan) that have a longstanding
history onALSmanagement, and are referral centers for ALS care
following >150patients/y each. They share an established
collaboration in the field of ALS, in clinical management of
patients, in the realization of clinical trials, genetic, and
epidemiological studies. The analysis of biomarkers will be
centralized and performed in a renowned laboratory (University
of Modena and Reggio Emilia), with large experience in cell
analysis and is internationally renowned for the use of flow
cytometry for studies on several human diseases. Randomization
and statistics will be also centralized to orchestrate the different
phases of the project. Statistical Unit of the University of Modena
and Reggio Emilia has considerable experience on RCT project
and management, and on data analysis. All trial activities will be
monitored by a CRO.
Each center is expected1. to randomize ≥7 patients fulfilling including and excluding
criteria in a period of 12 months and to administer the
treatment for 18 weeks;
to provide 1 principal investigator and 1 neurologist to evaluate2.
including and excluding criteria, get an informed consent,
administer treatment, and assess primary and secondary outcome;
to provide a person who will send Rapamycin dosage to the3.
coordinating center and who will not see patients; and
to formally adhere to the practice parameters of the European4.
Federation of Neurological Societies concerning the standard-
ization of the management of the patient in terms of
ventilatory support and nutrition.
2.16. Ethics and dissemination
The study will be carried out in accordance with the Declaration
of Helsinki, as amended by the 64th WMA General Assembly,
Fortaleza, Brazil, October 2013.
The results of the study will be presented during scientific
symposia or published in scientific journals only after review and
written approval by the involved parties in full respect of the
privacy of the participating subjects.
An insurance company will provide insurance coverage for
damages emerging from the trial and involving test subjects
treated with the test compound.
3. Discussion
An urgent unmet need persists for effective therapies in ALS. The
absence of reliable biomarker for disease progression and drugs
activity is an important target to be addressed too. This is going to
Mandrioli et al. Medicine (2018) 97:24 www.md-journal.combe a randomized clinical trial using a drug (Rapamycin) which
potentially targets important mechanisms at play in ALS, in
particular autophagy and neuroinflammation.
Preliminary data show that in 2 cell lines, inhibition of mTOR
by Rapamycin reduced TDP43 fragments accumulation and
restored TDP-43 nuclear localization.[11] In murine and in human
stem cell-derived neurons and astrocytes with mutant TDP43,
autophagy enhancement improved TDP43 clearance and
localization and enhanced survival, showing that autophagy
induction mitigates neurodegeneration by TDP43 clearance.[9] In
cultured neuronal cells expressing mutant ALS-causing FUS,
Rapamycin reduced FUS-positive stress granules, as well as
neurite fragmentation and cell death in neurons expressing
mutant FUS under oxidative stress.[12] In induced pluripotent
stem cells derived from ALS patient, activation of autophagic
mechanisms with Rapamycin reduced the accumulation of
p62.[13]
Early Rapamycin administration to a mouse model with FTLD
and cytoplasmic TDP43 ubiquinate inclusions (UBIs) rescued
learning/memory deficiencies and motor function disorders. This
was associated with reduction of neuronal loss and of TDP43
UBIs.[14] Treatment of zebrafish embryos with Rapamycin
yielded an amelioration of locomotor phenotype in a SQSTM1
knock-down model.[15]
Treatment with Rapamycin of larvae of a Drosophila model
carrying VAPB (P58S) mutation determined reversal of VAP
(P58S) bouton phenotypes, and Rapamycin decreased the
severity locomotive defects in a TDP-43/ALS Drosophila
model.[16,17]
Furthermore, inducing autophagy with Rapamycin was shown
to improve in vivo pathology of transgenic mice harboring a
disease-causing VCP mutation.[18]
However, the failure of Rapamycin with aggravation of
neuronal death has also been reported in mSOD1 mice. In this
study, mSOD1 mice (which reflects the pathogenic mechanisms
of SOD1 ALS, whereas the majority of ALS presents TDP43
UBIs) were treated with 2mg/kg body weight/d, a dosage >50
times higher than that used in clinical practice (usually 2mg/d),
which gives blood concentrations that have well known toxic
effects. A further study showed that this effect was due to
excessive immunosuppression, as the treatment on ALS mice
lacking mature lymphocytes increased ALS survival.[23] Howev-
er, being the evidences on Rapamycin action mainly on models
linked to TDP43 pathology, we will exclude patients carrying
SOD1 mutations.
As mTOR has a role in organisms longevity,[7] Rapamycin has
been tested to this extent and it resulted to extend the lifespan of
various mouse strains.[24] Rapamycin, then, has been shown to
protect against several types of neuronal injury (stroke,
atherosclerosis, traumatic brain, and spine injury). Recently, it
resulted effective in improving respiratory function in lymphan-
gioleiomyomatosis.[25]
Rapamycin has a well-known immunosuppressive action: it is
used for the cure of transplanted patients, and in clinical trials to
test efficacy in autoimmune disorders, CNS tumors, and other
neurological disorders (such as tuberous sclerosis).
As for the role of immunity in ALS, recent studies suggest that
innate and adaptive immune systems contribute to ALS
progression: Msod1 Tregs cocultured with activated Msod1
microglia attenuated the expression of microglial toxic factors by
IL4 release, and promoted MN survival by suppressing M1
activation, inducing an M2 protective phenotype, and reducing
the release of ROS. Tregs passive transfer into ALS mice9prolonged survival, and FoxP3 mRNA in mSOD1 mice spinal
cord decreased with disease progression.[8] In patients, blood
Treg percentage inversely correlated with ALS progression rate,
and FoxP3 levels were early predictors of ALS progression and
survival. These data were confirmed in postmortem studies.[8]
Inhibiting the mTOR pathway, Rapamycin induces de novo
FoxP3 expression and expands Treg.
The entity of the increase of Tregs induced by Rapamycin is
completely unknown in ALS patients. For this reason, we are
planning this first trial focused on showing immunological
targets engagement by Rapamycin in ALS patients. Moreover,
given its large natural structure, there was initial concern
that Rapamycin might not be able to cross the BBB; however,
in one study sufficient levels of Rapamycin could be found in
brain tumors when administered at therapeutic doses.[26] To
further address this concern, we are planning to test
Rapamycin titer in CSF at treatment end with LC–MS/MS
(using HPLC). This procedure will also allow to understand if
Rapamycin action depends on BBB crossing or on its action on
Treg cells.
In conclusion, the study will give extensive inference to a
possible effect of Rapamycin on biomarkers of disease progres-
sion. Rapamycin is an already approved drug, with known
pharmacokinetics, which is available and therefore there is
significant possibility of transferability to patients, and of a rapid
translation to daily clinics.
This short study will optimize time and resources to get reliable
information for a following RCT to test Rapamycin clinical
efficacy in ALS.Acknowledgments
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